T2 Biosystems to Present at the 13th Annual Canaccord Genuity Medical Technology & Diagnostics Forum
November 15 2019 - 7:30AM
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company,”“T2,” or “T2
Biosystems”), a leader in the development and commercialization of
innovative medical diagnostic products for critical unmet needs in
healthcare, announced today that John McDonough, chairman and chief
executive officer, and John Sprague, chief financial officer, are
scheduled to present at the 13th Annual Canaccord Genuity Medical
Technology & Diagnostics Forum. The conference is being held on
Thursday, November 21, 2019 in New York City.
Mr. McDonough and Mr. Sprague are scheduled to present on
Thursday, November 21, 2019 at 2:30-3:00 p.m. ET. Mr. McDonough and
Mr. Sprague will be available for one-on-one meetings during the
conference. The presentation will be webcast live and available for
replay, and may be accessed by visiting the Investors/Events &
Presentations section of the Company’s website at
www.t2biosystems.com. A replay of the webcast will be available
shortly after the conclusion of the presentation and will be
archived on the Company's website for 90 days following the
presentation.
About T2 Biosystems T2 Biosystems, a
leader in the development and commercialization of innovative
medical diagnostic products for critical unmet needs in healthcare,
is dedicated to improving patient care and reducing the cost of
care by helping clinicians effectively treat patients faster than
ever before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, and T2Bacteria® Panel, which was recently
announced as the first and only in-vitro diagnostic test to receive
approval for a New Technology Add-on Payment (NTAP) by CMS, are
powered by the proprietary T2 Magnetic Resonance (T2MR®)
technology. T2 Biosystems has an active pipeline of future
products, including products for the detection of additional
species and antibiotic resistance markers of sepsis pathogens, and
tests for Lyme disease. For more information, please visit
www.t2biosystems.com.
Media Contact: Gina Kent, Vault
Communications gkent@vaultcommunications.com 610-455-2763
Investor Contact: Zack Kubow, W2O Group
zkubow@w2ogroup.com 415-658-6436
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Sep 2024 to Oct 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Oct 2023 to Oct 2024